Sector: Healthcare · Industry: 生技醫療業 · Exchange: TWSE
PharmaEssentia Corporation, a biopharmaceutical company engages in medicine discovery, supplements in developing specialty pharmaceutical reagents, API, and new drug patterns developments in the Americas, Europe, Asia, and Taiwan. Its products include BESREMi, an interferon therapy indicated for polycythemia vera, essential thrombocythemia, PMF, and adult T-cell leukemias. The company also develops Ropeg + anti PD-1; PEG-IL-2 (P11838); PEG-Cytokines; PD-1-IL-2v; ADC; ADCS; NY-ESO-1 TCR-T; and Novel TCR-T for the treatment of solid tumor and immunology. PharmaEssentia Corporation was founded in 1990 and is headquartered in Taipei, Taiwan.
Headquarters: Taipei, TW · Website: https://www.pharmaessentia.com
藥華藥 (6446) is a publicly traded company in the Healthcare sector (生技醫療業), listed on TWSE. Macroplane maps its supply-chain relationships, suppliers, buyers, financial health, and competitive positioning.
Search companies · Macro trends · Industries · Product categories · Baskets